Abstract

Abhishek Meena, Anshu Patel, Dr. Rita Mourya, Dr. Shailesh Jain

ABSTRACT

Targeted drug delivery systems represent a paradigm shift in cancer therapeutics, offering the promise of enhanced therapeutic efficacy while minimizing systemic toxicity. This review examines the latest advances in targeted drug delivery technologies for cancer treatment, including passive and active targeting strategies, novel nanocarrier platforms, and emerging therapeutic approaches. We discuss the evolution from conventional chemotherapy to precision nanomedicine, highlighting key developments in liposomal formulations, polymeric nanoparticles, antibody-drug conjugates, and next-generation delivery vehicles. The review critically analyzes the clinical translation challenges, regulatory considerations, and future perspectives in the field. Recent clinical trials demonstrate significant improvements in therapeutic outcomes, with several targeted delivery systems achieving FDA approval and many more in advanced clinical phases. Current research focuses on overcoming biological barriers, enhancing tumor penetration, and developing personalized delivery strategies based on tumor microenvironment characteristics and patient-specific factors.